The AA2-Ratio: A Novel Diagnostic Biomarker for Primary Aldosteronism

Informazioni relative al progetto

PANOSTICS

ID dell’accordo di sovvenzione: 673072

DOI

10.3030/673072

Progetto chiuso

Data della firma CE 22 Aprile 2015

Data di avvio 1 Aprile 2015

Data di completamento 31 Agosto 2015

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

ATTOQUANT DIAGNOSTICS GMBH
Austria

Periodic Reporting for period 1 - PANOSTICS (The AA2-Ratio: A Novel Diagnostic Biomarker for Primary Aldosteronism)

Periodo di rendicontazione: 2015-04-01 al 2015-08-31

Sintesi del contesto e degli obiettivi generali del progetto

PANOSTICS is a biomarker implementation project conducted by Attoquant Diagnostics GmbH, a mass spectrometry service provider based in Vienna, Austria. Attoquant is specialized in the quantification of peptide hormones in biological samples by mass spectrometry, with a special focus on the patient specific profiling of the Renin-Angiotensin-Aldosterone-System, a peptide hormone system that is critically involved in the regulation of blood pressure. Attoquant’s services like the proprietary RAS-FingerprintTM are appreciated by research groups and biotech companies in the field world-wide and represent high quality diagnostic tools that are used in biomarker research and for the development of personalized treatment schemes in cardiovascular diseases like hypertension. The main objective of this Phase I of PANOSTICS was the development of a business and commercialization strategy for the validation and clinical implementation of the AA2-Ratio as a novel diagnostic biomarker for primary aldosteronism (PA) in hypertensive patients.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Technical and economic risks were assessed in detail and national healthcare systems as well as regulatory requirements were analyzed in terms of financial and regulatory aspects in order to identify preferred sites of market entry. Clinical centers being specialized in the diagnosis of PA have been identified and a validation study aimed to proof the enhanced diagnostic performance of the AA2-Ratio in the detection of PA has been designed under consideration of statistical requirements. Different commercialization scenarios have been assessed in terms of economic feasibility and marketing and distribution strategies for target markets have been developed.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

The AA2-Ratio represents a novel concept of PA diagnostics that is applicable in patients on anti-hypertensive therapy. This serves as the basis for the widespread implementation of PA screening into clinical routine of hypertension management, which would greatly improve the cure rate for PA and therefore prevent a significant number of cardiovascular events caused by uncontrolled hypertension. The focus of this project was the development of an implementation and commercialization plan aiming to make the AA2-Ratio available for hypertensive patients in Europe. The test will be based on the quantification of certain hormones in patient serum samples by mass spectrometry and will be offered as a diagnostic service to specialized clinical centers
PA is a severe, but curable form of treatment resistant hypertension. Treatment resistant hypertension affects more than 1 out of 50 Europeans and clinical guidelines recommend screening for PA among this high cardiovascular risk patient cohort. Unfortunately, adherence to these guidelines in clinical practice is poor, which is caused by the low diagnostic performance of currently available tests in patients on anti-hypertensive therapy and results in a high number of preventable cardiovascular events. The broad implementation of the AA2-Ratio into clinical practice would result in an improvement of the cure rate for PA and therefore prevent hypertension associated cardiovascular events, which are major cost drivers for health care systems in Europe.

The AA2-Ratio - Direct Ways in the Diagnosis of Primary Aldosteronism